Volume 8, Number 5—May 2002
Perspective
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
Table 1
Prechallenge neutralization titers of Ebola virus (EBOV)-vaccinated monkeys
Nonhuman primate species | No. of animals | Vector | Antigen | Neutralization titersa |
---|---|---|---|---|
Cynomolgus | 3 | Replicon | GP | 0, 0, 0 |
Cynomolgus | 3 | Replicon | NP | 0, 0, 0 |
Cynomolgus | 3 | Replicon | GP + NP | 0, 0, 10 |
Cynomolgus | 3 | Replicon | Influenza HA | 0, 0, 0 |
Cynomolgus | 3 | Vaccinia | GP | 10, 20, 20 |
Cynomolgus | 3 | Liposome | Inactivated virion | 20, 40, 80 |
Cynomolgus | 2 | Inactivated virion | 10, 20 | |
Rhesus | 2 | Inactivated virion | 10b, 20 | |
Cynomolgus | 2 | None | 0, 0 | |
Rhesus | 2 | None | 0, 0 |
aImmunoglobulin G enzyme-linked immunosorbent assay, neutralizing antibody (PRNT50) All vaccinated monkeys seroconverted by enzyme-linked immunosorbent assay before challenge.
bAnimal survived challenge.
GP, glycoprotein; NP, nucleoprotein.